Research with a destination | A question to investigate
The result should survive a second pair of hands.
A convincing chart is only useful if another person can understand how it was made. We are interested in research partnerships that make medicines analysis easier to reproduce, challenge and update when the source data changes.
A number has a journey before it reaches a page.
A medicines dataset can pass through downloads, exclusions, classifications, joins and calculations before it becomes a headline. Small choices along that journey can change its interpretation. Our proposed work examines those choices explicitly. The aim is a useful analytical record linking the question, the source and the transformation, so a reviewer can distinguish an observed value from a derived measure and an assumption from an established fact.
Begin with a question that public data can answer.
A suitable first project might compare national dispensing patterns across therapy categories or investigate how changes in cost and volume interact over time. The scope would follow the data's definitions and coverage. Public totals cannot establish an individual pharmacy's profitability, the appropriateness of a prescription or an avoidable saving. We would choose a question whose answer remains meaningful when those limitations are stated plainly.
Build the comparison twice.
We propose an independently reproduced analysis using the same frozen source files and a documented specification. One analyst could prepare the initial result while another follows the specification without relying on the first person's working notes. Differences would be reconciled at the level of filters, units and calculations. The comparator is the current analytical workflow, including the time needed to resolve disagreements and make the result usable by someone else.
Test the fragile points deliberately.
A robust analysis should cope with missing categories, renamed fields, changed coverage and rounding without silently producing a plausible mistake. We would create checks around totals, denominators and permitted transformations. Sensitivity analysis would show what happens when reasonable classification choices differ. The goal is not a perfect-looking line: it is an explanation that survives scrutiny and makes clear which conclusions are stable and which depend on a particular choice.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
An academic or development team examining the next experiment after a published model comparison.
What does this result allow us to ask next?
A promising figure can sharpen a research question. Its value depends on keeping the model, observation and next hypothesis distinct.
A proposition to investigate
A clearer question can be a useful output.
An evidence brief could help a team distinguish a published observation from the experiment needed to investigate translation. The proposed value is a more precise comparison and an explicit evidence gap. It does not turn an external model result into a clinical claim or a NEUVIOR discovery.
This is a constructed research-planning question, not an agreed study or product-development result.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a specific follow-on question has a credible experimental comparison.
- The comparator
- A scientifically justified model or condition relevant to the proposed hypothesis.
- The evidence
- Full methods, model relevance, measurements, replication and a feasible authorised protocol.
- Stop or redesign
- Stop or redesign if the proposed model cannot answer the question or the required work is not feasible.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefMake the output useful beyond the original analyst.
The proposed deliverable is a source-backed analytical notebook or equivalent reproducible package, a concise interpretation and an update procedure. A professional reader should be able to see the population, time period, exclusions and comparison without inspecting every technical detail. A technical reviewer should be able to recreate the calculations. Both perspectives matter if the analysis is to support a later research proposal or commercial discussion.
Openness needs judgement as well as enthusiasm.
UKRI's data-sharing guidance allows for legitimate restrictions, while its integrity guidance sets expectations for responsible research conduct (UKRI, n.d.; UKRI, n.d.). Our project-specific plan would establish licences, attribution and what can be shared before processing begins. Public source data does not automatically permit unrestricted use of every accompanying asset. Any organisational data introduced later would require a separate review of access, purpose and disclosure rather than inheriting the public-data arrangement.
A clear test for continuation.
The first collaboration should end with an independent reproduction report and a list of unresolved differences. We would expand only if the analysis can be recreated, its limitations remain understandable and the update effort is proportionate to the decision it supports. We would stop or narrow the question if source changes cannot be reconciled, definitions make comparison misleading or the apparent insight disappears under reasonable alternative assumptions. A corrected conclusion is a valuable result.
One useful output would distinguish changes in item counts from changes in total ingredient cost, then show where the direction differs across categories. A user could inspect the underlying totals and definitions before choosing a more detailed question. That exploration should explain the observed pattern without pretending to identify its cause from national aggregates alone.
Sources and context
UKRI (n.d.) Making your research data open. Available at: https://www.ukri.org/manage-your-award/publishing-your-research-findings/making-your-research-data-open/ (Accessed: 14 October 2026).
UKRI (n.d.) Research integrity. Available at: https://www.ukri.org/manage-your-award/good-research-resource-hub/research-integrity/ (Accessed: 14 October 2026).
Another useful angle.
- Evidence review quality
Explore a proposed medicines evidence study comparing source fidelity, review quality and total checking effort, with a clear decision for research partners.
- Research design for smaller businesses
Frame a focused research question for a medicines SME, compare realistic alternatives and identify the smallest experiment that could change its next decision.
- AI and professional judgement
Examine how professionals check, challenge and use AI outputs in medicines work, with proposed studies of appropriate reliance, review quality and total effort.














